Biocryst Pharmaceuticals Inc (BCRX) |
|
Price: $5.0000
$0.11
2.249%
|
Day's High:
| $5.115
| Week Perf:
| -6.02 %
|
Day's Low: |
$ 4.85 |
30 Day Perf: |
-10.23 % |
Volume (M): |
10,245 |
52 Wk High: |
$ 9.07 |
Volume (M$): |
$ 51,225 |
52 Wk Avg: |
$6.78 |
Open: |
$4.87 |
52 Wk Low: |
$4.82 |
|
|
Market Capitalization (Millions $) |
960 |
Shares
Outstanding (Millions) |
192 |
Employees |
192 |
Revenues (TTM) (Millions $) |
331 |
Net Income (TTM) (Millions $) |
-227 |
Cash Flow (TTM) (Millions $) |
-194 |
Capital Exp. (TTM) (Millions $) |
2 |
Biocryst Pharmaceuticals Inc
Biocryst Pharmaceuticals Inc. is a biotechnology company based in Durham, North Carolina that focuses on developing innovative drugs for the treatment of rare diseases. The company primarily focuses on developing small-molecule drugs designed to target specific enzymes or proteins in the body that are involved in the disease process. Biocryst's current pipeline includes a diverse range of drug candidates, including orally-administered treatments for hereditary angioedema (HAE), a rare genetic disorder that causes sudden and severe swelling attacks; Alport syndrome, a rare genetic disorder that affects the kidneys and can lead to kidney failure; and non-alcoholic steatohepatitis (NASH), a type of liver disease that is associated with obesity and diabetes. Their lead candidate is Orladeyo, an oral medication approved by the FDA for the prevention of HAE attacks in adults and adolescents over the age of 12. Biocryst is also continuing to work on new indications for Orladeyo and is exploring the potential for it to be used in combination with other medications or as a monotherapy. Another key focus area for Biocryst is developing antiviral drugs. They have several candidates in their program, including Galidesivir, which has shown promise in treating a number of viral diseases, including influenza, Ebola, and most recently, COVID-19. Overall, Biocryst Pharmaceuticals Inc. has a strong track record of developing innovative drugs to treat rare diseases, and their ongoing research and development efforts position them as a leader in the biotechnology industry.
Company Address: 4505 Emperor Blvd., Suite 200 Durham 27703 NC
Company Phone Number: 859-1302 Stock Exchange / Ticker: NASDAQ BCRX
|
|
|
|
|
Stock Performances by Major Competitors |
|
|
Shares
Published Tue, Mar 5 2024 12:01 PM UTC
Biocryst Pharmaceuticals Inc. recently announced the issuance of inducement grants to three newly-hired employees in the form of stock options and restricted stock units (RSUs), as outlined in their press release on March 05, 2024. These grants were given to the employees as an incentive to join the company and were made in accordance with Nasdaq Listing Rule 5635(c)(4)...
|
Biocryst Pharmaceuticals Inc
ntributor In a recent groundbreaking announcement, BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) has unveiled new analyses of real-world usage of ORLADEYO (berotralstat), an oral, once-daily treatment for hereditary angioedema (HAE). These findings showcase the significant reduction in attack rates experienced by patients who initiated ORLADEYO therapy, regardless of the severity of their disease, prior prophylaxis history, or their C1-inhibitor (C1-INH) level and function. This marks a potential breakthrough in the management of HAE, instilling hope among those affected by this rare and debilitating condition. HAE, a rare genetic disorder characterized by unpredictable and recurrent swelling attacks in various body parts, has long presented a challenge for patients and healthcare providers alike. These attacks can cause immense pain, disfigurement, and potential life-threatening situations, impacting patients' physical, emotional, and social well-being. Traditionally, HAE management has relied on acute treatments and prophylactic measures to prevent and reduce the occurrence of attacks. However, the advent of ORLADEYO, a long-term, once-daily oral treatment, represents a significant advancement and potential game-changer in the field.
|
Product Service News
Published Fri, Feb 23 2024 12:00 PM UTC
BioCryst Presents New Real-world Data Showing Rapid, Substantial and Sustained HAE Attack Rate Reductions After Beginning ORLADEYO (berotralstat) TreatmentRESEARCH TRIANGLE PARK, N.C., Feb. 23, 2024 - In a groundbreaking announcement, BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) revealed new analyses of real-world usage of ORLADEYO (berotralstat), an oral, once-daily treatme...
|
Product Service News
Published Mon, Feb 19 2024 12:55 PM UTC
In recent news, BioCryst Pharmaceuticals, Inc. has made significant strides in improving the treatment options available for patients with hereditary angioedema (HAE) and has also unveiled promising developments in its pipeline. This article discusses the recent launch of ORLADEYO (berotralstat) in Italy as a breakthrough oral therapy for the prevention of recurrent HAE atta...
|
Shares
Published Fri, Feb 2 2024 12:01 PM UTC
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) RESEARCH TRIANGLE PARK, N.C., Feb. 02, 2024 - BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) has recently announced the granting of stock options and restricted stock units (RSUs) to newly-hired employees. The compensation committee of BioCryst's board of directors granted a total of 32,100 shares thr...
|
Per Share |
Current |
Earnings (TTM) |
-1.17 $ |
Revenues (TTM) |
1.73 $
|
Cash Flow (TTM) |
- |
Cash |
2.04 $
|
Book Value |
-
|
Dividend (TTM) |
0 $ |
|
Per Share |
|
Earnings (TTM) |
-1.17 $
|
Revenues (TTM) |
1.73 $ |
Cash Flow (TTM) |
- |
Cash |
2.04 $
|
Book Value |
- |
Dividend (TTM) |
0 $ |
|
|
|
Company Estimates |
|
|
• Revenue Outlook
Biocryst Pharmaceuticals Inc does not provide revenue guidance.
• Earnings Outlook
Biocryst Pharmaceuticals Inc does not provide earnings estimates.
|
|
|
|
|
|